Aer Therapeutics

About Aer Therapeutics

Aer Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel inhaled therapies to treat respiratory diseases characterized by excess mucus and mucus plugs, such as COPD, cystic fibrosis, and asthma. The company employs state-of-the-art lung imaging and analysis techniques to identify patients with clinically silent airway mucus plugs and to measure the efficacy of their thiol saccharide mucolytics. These mucolytic agents are designed to clear thick mucus from the lungs, improve airflow, and restore lung health. Aer Therapeutics serves patients with moderate to severe forms of COPD and asthma, addressing significant unmet medical needs in the respiratory market. The business model revolves around the discovery, clinical development, and commercialization of these respiratory therapies. Revenue is generated through the development and eventual sale or licensing of their proprietary inhaled mucolytic agents. The company is led by a globally experienced management team and scientific advisory board with a proven track record in respiratory therapy development.